Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 229-234

  Wu, William K A Kei ^a   Tse, Timothy Tim Ming ^a   Sung, Joseph Jao Yiu ^a   Li, Zhi Jie ^a   Yu, Le ^a   Cho, Chi Hin ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colon cancer; ErbB; Gastric cancer; Neuroglycan C; Proliferation

Indexed keywords

BETACELLULIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIGEN; EPIREGULIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERPHOTORECEPTOR MATRIX PROTEOGLYCAN 2; MEPRIN; MUCIN 12; MUCIN 17; MUCIN 3; MUCIN 4; NEUROGLYCAN C; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CELL PROLIFERATION; COLON CANCER; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; STOMACH CANCER;

ADENOCARCINOMA; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; EPIDERMAL GROWTH FACTOR; HT29 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; NEUREGULINS; ONCOGENE PROTEINS V-ERBB; PROTEOCHONDROITIN SULFATES; STOMACH NEOPLASMS;

EID: 61449229472     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Massie C and Mills IG: The developing role of receptors and adaptors. Nat Rev Cancer 6: 403-409, 2006.
2. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
3. Hynes NE and Schlange T: Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 10: 7-11, 2006.
4. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005.
5. Kari C, Chan TO, Rocha de Quadros M and Rodeck U: Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63: 1-5, 2003.
6. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD and Maity A: EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66: 3197-3204, 2006.
7. Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD and Grandis JR: Epidermal growth factor receptor-stimulated activation of phospholipase C gamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 63: 5629-5635, 2003.
8. Linggi B and Carpenter G: ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16: 649-656, 2006.
9. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
10. Park OK, Schaefer TS and Nathans D: In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci USA 93: 13704-13708, 1996.
11. Kauffmann-Zeh A, Thomas GM, Ball A, Presser S, Cunningham E, Cockcroft S and Hsuan JJ: Requirement for phosphatidylinositol transfer protein in epidermal growth factor signaling. Science 268: 1188-1190, 1995.
12. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 305: 1163-1167, 2004.
13. Stein RA and Staros JV: Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol 6: 79, 2006.
14. Sanderson MP, Dempsey PJ and Dunbar AJ: Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 24: 121-136, 2006.
15. Ferrer-Soler L, Vazquez-Martin A, Brunei J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleocytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20: 3-10, 2007.
16. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA and Arteaga CL: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919, 2007.
17. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
18. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C and Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
19. Noguchi H, Sakamoto C, Wada K, Akamatsu T, Uchida T, Tatsuguchi A, Matsui H, Fukui H, Fujimori T and Kasuga M: Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. Gastroenterology 117: 1119-1127, 1999.
20. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX and DuBois RN: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713-1719, 2001.
21. Kapitanovié S, Radosević S, Kapitanović M, Andelinović S, Ferencić Z, Tavassoli M, Primorać D, Sonicki Z, Spaventi S, Pavelic K and Spaventi R: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112: 1103-1113, 1997.
22. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M, Fukuyama K, Yamamoto K, Mekada E and Sasazuki T: Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 60: 6886-6889, 2000.
23. Jackson JG, St Clair P, Sliwkowski MX and Brattain MG: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601-2609, 2004.
24. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E and Miyamoto S: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561, 2008.
25. Karnes WE Jr, Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, Mendelsohn J, Park JG and Cuttitta F: Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. Gastroenterology 102: 474-485, 1992.
26. Watanabe E, Maeda N, Matsui F, Kushima Y, Noda M and Oohira A: Neuroglycan C, a novel membrane-spanning chondroitin sulfate proteoglycan that is restricted to the brain. J Biol Chem 270: 26876-26882, 1995.
27. Kinugasa Y, Ishiguro H, Tokita Y, Oohira A, Ohmoto H and Higashiyama S: Neuroglycan C, a novel member of the neuregulin family. Biochem Biophys Res Commun 321: 1045-1049, 2004.